Zhongda'an: Wu Junye, the controlling shareholder, plans to reduce his holdings by no more than 2%

Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying

The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

SHEIN Reportedly Targets US$26–27 Billion Valuation in Hong Kong IPO

SHEIN (希音), the China-founded global fashion and lifestyle retailer, is reportedly seeking a valuation of US$26 billion to US$27 billion in a planned Hong Kong initial public offering, a sharp reduction from the US$98.2 billion private-market valuation disclosed for its 2022 fundraising round.

Pony.ai’s Robotaxi Revenue Rises 691% as Overseas Deployment Pipeline Tops 4,000 Vehicles

Pony.ai reported a sharp acceleration in Robotaxi revenue in the second quarter of 2026, while outlining planned and potential overseas deployments exceeding 4,000 vehicles—signalling the company’s push to turn its China operating experience into a broader international business.

ByteDance’s Proposed US$20 Billion Offshore Loan Draws More Than US$30 Billion of Demand

ByteDance (字节跳动) has drawn more than US$30 billion of demand for a proposed syndicated loan that could become its largest offshore borrowing, Bloomberg reported on Aug. 19, underscoring lenders’ appetite to finance the TikTok owner’s expanding artificial-intelligence infrastructure plans.